登录 注册 会员服务 联系我们

Cost-minimization Analysis of S-1 Plus Irinotecan (IRIS) versus Oxaliplatin or Irinotecan Plus Fluorouracil and Folinic Acid (mFOLFOX6 or FOLFIRI) in Patients with Advanced Colorectal Cancer

  • Published:2015 Issue:3 Volume:41 Page:153-162
  • ISSN:1346-342X
  • Container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
  • language:en
  • Short-container-title:Jpn. J. Pharm. Health Care Sci.

Author:

Shimizu Hisanori1,Ikeda Shunya2,Sakamaki Hiroyuki3,Yajima Shuichi45,Ikegami Naoki4,Murayama Jun-Ichiro6

Affiliation:

1. Department of Pharmacy Services, Showa University Hospital

2. Department of Pharmaceutical Sciences, School of Pharmacy, International University of Health and Welfare

3. Department of Clinical Economics, Meijo University

4. Department of Health Policy and Management, School of Medicine, Keio University

5. Taiho Pharmaceutical Co, LTD

6. Department of Hospital Pharmaceutics, School of Pharmacy, Showa

Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference19 articles.

1. 1) Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, Gramont A, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomised GERCOR study, J Clin Oncol, 2004, 22, 229-237.

2. 2) Saltz BL, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Rivera F, Couture F, Sirzén F, Cassidy J, Bevacizumab in combination with oxaliplatin based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomised phase III study, J Clin Oncol, 2008, 26, 2013-2019.

3. 3) Cutsem VE, Kohne C, Hitre E, Zaluski J, Chang Chien C, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, Roh J, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P, Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, N Engl J Med, 2009, 360, 1408-1417.

4. 4) Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ, Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer, J Clin Oncol, 2011, 29, 1465-1471.

5. 5) Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K, Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT) : an open-label, non-inferiority, randomised phase 3 trial, Lancet Oncol, 2013, 14, 1278-1286.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3